Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy.

Phan M, Watson MF, Alain T, Diallo JS.

ACS Infect Dis. 2018 Oct 12;4(10):1448-1467. doi: 10.1021/acsinfecdis.8b00144. Epub 2018 Sep 12.

PMID:
30152676
2.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Zakaria C, Sean P, Hoang HD, Leroux LP, Watson M, Workenhe ST, Hearnden J, Pearl D, Truong VT, Robichaud N, Yanagiya A, Tahmasebi S, Jafarnejad SM, Jia JJ, Pelin A, Diallo JS, Le Boeuf F, Bell JC, Mossman KL, Graber TE, Jaramillo M, Sonenberg N, Alain T.

PLoS Pathog. 2018 Aug 23;14(8):e1007264. doi: 10.1371/journal.ppat.1007264. eCollection 2018 Aug.

3.

Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, Saad F, Singh SK, Diallo JS, Lichty BD.

Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018.

PMID:
29900060
4.

Intraoperative Findings of Lateral Ligament Avulsion Fractures and Outcome After Refixation to the Fibula.

Diallo J, Wagener J, Schweizer C, Lang TH, Ruiz R, Hintermann B.

Foot Ankle Int. 2018 Jun;39(6):669-673. doi: 10.1177/1071100718760273. Epub 2018 Mar 12.

PMID:
29528723
5.

Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Staphylococcus aureus Biofilms.

Kumaran D, Taha M, Yi Q, Ramirez-Arcos S, Diallo JS, Carli A, Abdelbary H.

Front Microbiol. 2018 Feb 5;9:127. doi: 10.3389/fmicb.2018.00127. eCollection 2018.

6.

Facial Fracture-Associated Blindness.

Béogo R, Coulibaly TA, Dolo MT, Traoré I, Ouattara B, Diallo JW.

J Craniofac Surg. 2018 May;29(3):751-753. doi: 10.1097/SCS.0000000000004378.

PMID:
29438207
7.

Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition.

Selman M, Ou P, Rousso C, Bergeron A, Krishnan R, Pikor L, Chen A, Keller BA, Ilkow C, Bell JC, Diallo JS.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaao1613. doi: 10.1126/scitranslmed.aao1613.

PMID:
29367345
8.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
9.

Success factors for implementing and sustaining a mature electronic medical record in a low-resource setting: a case study of iSanté in Haiti.

deRiel E, Puttkammer N, Hyppolite N, Diallo J, Wagner S, Honoré JG, Balan JG, Celestin N, Vallès JS, Duval N, Thimothé G, Boncy J, Coq NRL, Barnhart S.

Health Policy Plan. 2018 Mar 1;33(2):237-246. doi: 10.1093/heapol/czx171.

PMID:
29253138
10.

Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.

Selman M, Rousso C, Bergeron A, Son HH, Krishnan R, El-Sayes NA, Varette O, Chen A, Le Boeuf F, Tzelepis F, Bell JC, Crans DC, Diallo JS.

Mol Ther. 2018 Jan 3;26(1):56-69. doi: 10.1016/j.ymthe.2017.10.014. Epub 2017 Oct 24.

PMID:
29175158
11.

Congenital vitiligo: A case observed in the cohort of HIV-exposed infants in Bobo-Dioulasso, Burkina Faso.

Barro M, Diallo JW, Ouattara ABI, Nacro B.

Pediatr Rep. 2017 Oct 6;9(3):7300. doi: 10.4081/pr.2017.7300. eCollection 2017 Oct 6.

12.

Epidemiological profile of patients with uveitis in Boko and Parakou, in northern Bénin.

Ayena KD, Vonor K, Santos MAK, Sounouvou I, Odoulami-Yehouessi L, Diallo JW, Monteiro S, Nagbe YE, Balo K.

Med Sante Trop. 2017 Aug 1;27(3):315-318. doi: 10.1684/mst.2017.0702.

13.

Customized Viral Immunotherapy for HPV-Associated Cancer.

Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, Johnson-Obaseki S, Villeneuve PJ, Diallo JS, Dimitroulakos J, Wan Y, Lichty BD.

Cancer Immunol Res. 2017 Oct;5(10):847-859. doi: 10.1158/2326-6066.CIR-17-0102. Epub 2017 Sep 14.

14.

Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma.

Le Boeuf F, Selman M, Son HH, Bergeron A, Chen A, Tsang J, Butterwick D, Arulanandam R, Forbes NE, Tzelepis F, Bell JC, Werier J, Abdelbary H, Diallo JS.

Int J Cancer. 2017 Sep 15;141(6):1257-1264. doi: 10.1002/ijc.30813. Epub 2017 Jun 21.

15.

Instability adversely affects HIV care in Haiti.

Honoré JG, Balan JG, Thimothé G, Diallo J, Barnhart S.

Lancet. 2016 Oct 15;388(10054):1877. doi: 10.1016/S0140-6736(16)31804-9. No abstract available.

PMID:
27751392
16.

[Bilateral choroidal ischemia in preeclampsia/eclampsia: Report of 6 cases].

Diallo JW, Méda N, Ahnoux-Zabsonré A, Yanogo A, Tougouma SJ, Ouattara S, Sanou J, Dolo M.

J Fr Ophtalmol. 2016 Nov;39(9):e241-e245. doi: 10.1016/j.jfo.2015.10.014. Epub 2016 Sep 14. French. No abstract available.

17.

Single-particle characterization of oncolytic vaccinia virus by flow virometry.

Tang VA, Renner TM, Varette O, Le Boeuf F, Wang J, Diallo JS, Bell JC, Langlois MA.

Vaccine. 2016 Sep 30;34(42):5082-5089. doi: 10.1016/j.vaccine.2016.08.074. Epub 2016 Sep 8.

PMID:
27614781
18.

Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.

Bourgeois-Daigneault MC, St-Germain LE, Roy DG, Pelin A, Aitken AS, Arulanandam R, Falls T, Garcia V, Diallo JS, Bell JC.

Breast Cancer Res. 2016 Aug 8;18(1):83. doi: 10.1186/s13058-016-0744-y.

19.

First-in-class small molecule potentiators of cancer virotherapy.

Dornan MH, Krishnan R, Macklin AM, Selman M, El Sayes N, Son HH, Davis C, Chen A, Keillor K, Le PJ, Moi C, Ou P, Pardin C, Canez CR, Le Boeuf F, Bell JC, Smith JC, Diallo JS, Boddy CN.

Sci Rep. 2016 May 26;6:26786. doi: 10.1038/srep26786.

20.

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity.

Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, Garcia V, Selman M, Jennings VA, Pettigrew J, Amos S, Diallo JS, Nelson B, Bell JC.

Mol Ther Oncolytics. 2016 Feb 17;3:16001. doi: 10.1038/mto.2016.1. eCollection 2016.

21.

Oncolytic Viruses: Exploiting Cancer's Deal with the Devil.

Pikor LA, Bell JC, Diallo JS.

Trends Cancer. 2015 Dec;1(4):266-277. doi: 10.1016/j.trecan.2015.10.004. Epub 2015 Nov 21. Review.

PMID:
28741515
22.

[Ocular manifestations in severe pre-eclampsia or eclampsia in Souro Sanou University Hospital in Bobo Dioulasso].

Diallo JW, Méda N, Ahnoux-Zabsonré A, Ouattara S, Yanogo A, Tougouma SJ, Somé D, Sanou J, Dolo M.

Pan Afr Med J. 2015 May 25;21:49. doi: 10.11604/pamj.2015.21.49.6746. eCollection 2015. French. No abstract available.

23.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.

24.

[Interests of the examination of the fundus in general practice: review of 438 cases].

Diallo JW, Méda N, Tougouma SJ, Ahnoux-Zabsonré A, Yé R, Djiguimdé P, Sanou J, Sankara P, Méda G, Dolo M.

Pan Afr Med J. 2015 Apr 14;20:363. doi: 10.11604/pamj.2015.20.363.6629. eCollection 2015. French. No abstract available.

25.

[Functional outcomes of cataract surgery by phacoemulsification with implantation in the posterior chamber: 300 cases in Bobo Dioulasso (Burkina Faso)].

Diallo JW, Meda N, Ahnoux-Zabsonre A, Yameogo C, Dolo M, Sanou J, Daboue A.

Pan Afr Med J. 2015 Mar 12;20:230. doi: 10.11604/pamj.2015.20.230.6323. eCollection 2015. French. No abstract available.

26.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.

PMID:
25894825
27.

Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.

Arulanandam R, Batenchuk C, Varette O, Zakaria C, Garcia V, Forbes NE, Davis C, Krishnan R, Karmacharya R, Cox J, Sinha A, Babawy A, Waite K, Weinstein E, Falls T, Chen A, Hamill J, De Silva N, Conrad DP, Atkins H, Garson K, Ilkow C, Kærn M, Vanderhyden B, Sonenberg N, Alain T, Le Boeuf F, Bell JC, Diallo JS.

Nat Commun. 2015 Mar 30;6:6410. doi: 10.1038/ncomms7410.

PMID:
25817275
28.

High-throughput titration of luciferase-expressing recombinant viruses.

Garcia V, Krishnan R, Davis C, Batenchuk C, Le Boeuf F, Abdelbary H, Diallo JS.

J Vis Exp. 2014 Sep 19;(91):51890. doi: 10.3791/51890.

29.

Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.

Ruotsalainen JJ, Kaikkonen MU, Niittykoski M, Martikainen MW, Lemay CG, Cox J, De Silva NS, Kus A, Falls TJ, Diallo JS, Le Boeuf F, Bell JC, Ylä-Herttuala S, Hinkkanen AE, Vähä-Koskela MJ.

Gene Ther. 2015 Jan;22(1):65-75. doi: 10.1038/gt.2014.83. Epub 2014 Sep 18.

PMID:
25231172
30.

Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.

Forbes NE, Krishnan R, Diallo JS.

Front Oncol. 2014 Jul 23;4:191. doi: 10.3389/fonc.2014.00191. eCollection 2014. Review.

31.

Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells.

Garijo R, Hernández-Alonso P, Rivas C, Diallo JS, Sanjuán R.

PLoS One. 2014 Jul 10;9(7):e102365. doi: 10.1371/journal.pone.0102365. eCollection 2014.

32.

From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer.

Ilkow CS, Swift SL, Bell JC, Diallo JS.

PLoS Pathog. 2014 Jan;10(1):e1003836. doi: 10.1371/journal.ppat.1003836. Epub 2014 Jan 16. Review.

33.

Exploiting tumor epigenetics to improve oncolytic virotherapy.

Forbes NE, Abdelbary H, Lupien M, Bell JC, Diallo JS.

Front Genet. 2013 Sep 20;4:184. doi: 10.3389/fgene.2013.00184. Review.

34.

Model-based rational design of an oncolytic virus with improved therapeutic potential.

Le Bœuf F, Batenchuk C, Vähä-Koskela M, Breton S, Roy D, Lemay C, Cox J, Abdelbary H, Falls T, Waghray G, Atkins H, Stojdl D, Diallo JS, Kærn M, Bell JC.

Nat Commun. 2013;4:1974. doi: 10.1038/ncomms2974.

PMID:
23764612
35.

Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia.

Conrad DP, Tsang J, Maclean M, Diallo JS, Le Boeuf F, Lemay CG, Falls TJ, Parato KA, Bell JC, Atkins HL.

Clin Cancer Res. 2013 Jul 15;19(14):3832-43. doi: 10.1158/1078-0432.CCR-12-3199. Epub 2013 May 28.

36.

[Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses].

Pol J, Le Bœuf F, Diallo JS.

Med Sci (Paris). 2013 Feb;29(2):165-73. doi: 10.1051/medsci/2013292014. Epub 2013 Feb 28. Review. French.

37.

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y.

Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8.

38.

[Generalized elastic and evolving pseudoxanthoma in a black].

Andonaba JB, Barro-Traoré F, Korsaga S, Diallo B, Diallo JW, Traoré A.

Pan Afr Med J. 2013 Dec 9;16:132. doi: 10.11604/pamj.2013.16.132.3316. eCollection 2013. French. No abstract available.

39.

Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma.

Vähä-Koskela MJ, Le Boeuf F, Lemay C, De Silva N, Diallo JS, Cox J, Becker M, Choi Y, Ananth A, Sellers C, Breton S, Roy D, Falls T, Brun J, Hemminki A, Hinkkanen A, Bell JC.

J Virol. 2013 Feb;87(4):2363-6. doi: 10.1128/JVI.01609-12. Epub 2012 Dec 5.

40.

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC, Auer RC.

Mol Ther. 2012 Sep;20(9):1791-9. doi: 10.1038/mt.2012.128. Epub 2012 Jul 3.

41.

[What remains today of neonatal conjunctivitis in prefecture of Kozah in Togo?].

Ayena KD, Amedome KM, Diallo JW, Dzidzinyo KB, Azoumah KD, Aboubakari AS, Salou M, Koffi SK, Tchassi N, Balo KP.

J Fr Ophtalmol. 2012 Jun;35(6):432-6. doi: 10.1016/j.jfo.2011.10.006. Epub 2012 Apr 11. French.

42.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

43.

Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains.

Diallo JS, Vähä-Koskela M, Le Boeuf F, Bell J.

Methods Mol Biol. 2012;797:127-40. doi: 10.1007/978-1-61779-340-0_10.

PMID:
21948474
44.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH.

Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358.

PMID:
21886163
45.

[Eales disease: a case report in Burkina Faso].

Diallo JW, Nikiema Z, Daboue A, Tieno H, Meda N, Kan GR.

J Fr Ophtalmol. 2011 Oct;34(8):539-42. doi: 10.1016/j.jfo.2011.01.011. Epub 2011 Jul 30. French.

46.

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH.

Mol Ther. 2011 Oct;19(10):1913-22. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19.

47.

Ex vivo infection of live tissue with oncolytic viruses.

Diallo JS, Roy D, Abdelbary H, De Silva N, Bell JC.

J Vis Exp. 2011 Jun 25;(52). pii: 2854. doi: 10.3791/2854.

48.

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.

MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T, McCart JA, Atkins H, Breitbach C, Kirn D, Thorne S, Bell JC.

PLoS One. 2010 Dec 30;5(12):e14462. doi: 10.1371/journal.pone.0014462.

49.

Influence of pH on the Cytotoxic Activity of Inositol Hexakisphosphate (IP6) in Prostate Cancer.

Betton B, Gannon PO, Koumakpayi IH, Diallo JS, Mes-Masson AM, Saad F.

Front Oncol. 2011 Oct 31;1:40. doi: 10.3389/fonc.2011.00040. eCollection 2011.

50.

A novel method of cell embedding for tissue microarrays.

Zietarska M, Madore J, Diallo JS, Delvoye N, Saad F, Provencher D, Mes-Masson AM.

Histopathology. 2010 Aug;57(2):323-9. doi: 10.1111/j.1365-2559.2010.03602.x. No abstract available.

PMID:
20716176

Supplemental Content

Loading ...
Support Center